Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19

The emerging upsurge of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has resulted in a global pandemic which originated in Wuhan city, China. The complicated virology of SARS CoV-2 makes it difficult to evaluate the therapeutic management for this infection. Drug repurposing is been...

Full description

Bibliographic Details
Main Authors: Justin Jacob Abraham, I Jerlin Michelle, S A Shevaani, Kiran Kumar Rathinam, Muhasaparur Ganesan Rajanandh, Vijayakumar Thangavel Mahalingam
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Current Medicine Research and Practice
Subjects:
covid-19
cytokine release syndrome
interleukin 6
monoclonal antibody
sarilumab
Online Access:http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=6;spage=280;epage=283;aulast=Abraham

Internet

http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=6;spage=280;epage=283;aulast=Abraham

Similar Items